22Jul/13

U.S. Launch of Astellas' Astagraf XL – Analyst Blog – NASDAQ


MedPage Today

U.S. Launch of Astellas’ Astagraf XL – Analyst Blog
NASDAQ
received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab
Long-Release Tacrolimus Wins FDA NodMedPage Today
New Treatment Option for Kidney Transplant RecipientsMonthly Prescribing Reference
FDA approves Astellas once-daily organ rejection drugPharmaTimes
Genetic Engineering News –NephrologyNews.com –The Pharma Letter
all 8 news articles »